Daily cup of coffee may prevent afib recurrence
Gene-editing therapy lowers harmful blood fats in early study
What is EMDR therapy, and who can it help?
GLP-1 drugs versus bariatric surgery for treating obesity
Trying to lose weight? Be careful not to lose muscle
Two dumbbells, three exercises, and 10 minutes
Easing the emotional burden of IBS
Modify your push-ups to meet your fitness level
What is long QT syndrome?
Stroke survivors may benefit from very low LDL levels
Adam S. Cheifetz, MD
Contributor
Dr. Adam Cheifetz is director of the center for inflammatory bowel disease and medical director of infusion services at Beth Israel Deaconess Medical Center, and professor of medicine at Harvard Medical School. He is a well-recognized leader in the treatment of Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases. He is involved in multiple research projects relating to IBD, and has published over 200 articles and chapters on the subject.
His research currently focuses on therapeutic drug monitoring and optimizing the use of biologics through the proactive use of drug concentrations and antibodies, and he has published extensively in this area. Dr. Cheifetz was the first to demonstrate that proactive monitoring of infliximab and adalimumab concentrations and dosing to a therapeutic window improves outcomes when compared to standard of care.
Daily cup of coffee may prevent afib recurrence
Gene-editing therapy lowers harmful blood fats in early study
What is EMDR therapy, and who can it help?
GLP-1 drugs versus bariatric surgery for treating obesity
Trying to lose weight? Be careful not to lose muscle
Two dumbbells, three exercises, and 10 minutes
Easing the emotional burden of IBS
Modify your push-ups to meet your fitness level
What is long QT syndrome?
Stroke survivors may benefit from very low LDL levels
